JNJ-39758979 + methotrexate

**JNJ-39758979 + methotrexate** is a combination therapy comprising JNJ-39758979, a small molecule antagonist of the histamine H4 receptor, and methotrexate, a conventional disease-modifying antirheumatic drug (DMARD)[1][3][4][7]. JNJ-39758979, developed by Janssen Research & Development, was investigated for immune-mediated diseases such as rheumatoid arthritis, atopic dermatitis, and asthma, with the mechanism being selective antagonism of histamine H4 receptor, aiming to reduce inflammation and pruritus[3][4][5][9]. Methotrexate, widely used for rheumatoid arthritis, acts as an anti-folate and immunosuppressant by inhibiting dihydrofolate reductase and other folate-dependent pathways. The combination was evaluated, notably in clinical trial NCT01480388, for the treatment of **active rheumatoid arthritis in patients with inadequate response to methotrexate alone**[1][6][8]. JNJ-39758979 use was discontinued after phase II trials due to lack of clinical efficacy and safety concerns, particularly drug-induced agranulocytosis and neutropenia[2][3][9].

Other names

JNJ 39758979 + methotrexatejnj39758979 + methotrexate1046447-90-8 + methotrexate4-[(3R)-3-aminopyrrolidin-1-yl]-6-propan-2-ylpyrimidin-2-amine + methotrexate